Loading clinical trials...
Loading clinical trials...
Asciminib as Initial Therapy With Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia Who do Not Achieve Optimal Response or a Deep Molecular Remission (ALERT CML)
Conditions
Interventions
Single Agent Asciminib
Low TKI
+1 more
Locations
7
United States
Winship Cancer Institute Emory University
Atlanta, Georgia, United States
Georgia Cancer Center at Augusta University
Augusta, Georgia, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Huntsman Cancer Institute
Salt Lake City, Utah, United States
Start Date
April 22, 2022
Primary Completion Date
February 1, 2032
Completion Date
February 1, 2032
Last Updated
March 23, 2026
NCT07216443
NCT06852222
NCT06580106
NCT06501196
NCT06384261
NCT06382168
Lead Sponsor
Augusta University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions